Bladder cancer: Natural history, tumor markers, and early detection strategies

Seminars in Surgical Oncology

Volumn 13, Issue 5, 1997, Pages 299-306

  Foresman, William H ^a,b   Messing, Edward M ^a  

^a STRONG MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Antigens; Biological tumor markers; Bladder neoplasms; Carcinoma in situ; Hematuria; Neoplasm invasiveness; Oncogenes; P53 gene; Retinoblastoma protein; Transitional cell carcinoma; Tumor suppressor genes; Urothelium

Indexed keywords

AUTOCRINE MOTILITY FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CYCLIN DEPENDENT KINASE; CYCLINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MATRIX PROTEIN; MICROSATELLITE DNA; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR ANTIGEN; TUMOR MARKER; UROKINASE;

ANTIGEN EXPRESSION; BLADDER CARCINOMA; BLOOD GROUP LEWIS SYSTEM; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CARCINOMA IN SITU; CHROMOSOME 13; CHROMOSOME 17; CHROMOSOME 9; CHROMOSOME ANALYSIS; EARLY DIAGNOSIS; HUMAN; PRIORITY JOURNAL; REVIEW; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; HEMATURIA; HUMANS; MUSCLE, SMOOTH; NEOPLASM INVASIVENESS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0030861027     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199709/10)13:5<299::AID-SSU3>3.0.CO;2-8     Document Type: Review

References (45)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997, Ca J Clin 1997;47:5-27.
2. Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M, et al: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784-788
3. Dalbagni G, Presti J, Reuter V, et al: Genetic alterations in bladder cancer. Lancet 1993;342(8869):469-471.
4. Heney NM, Ahmed S, Flanagan MJ, et al: Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083-1086
5. Messing EM, Catalona W: Urothelial tumors of the urinary tract. In Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds): "Campbell's Urology." Philadelphia: Saunders, 7th ed. In press.
6. Kroft SH, Oyasu R: Urinary bladder cancer: mechanisms of development and progression. [Review] Lab Invest 1994;71:158-174.
7. Messing EM, Young TB, Hunt VB, et al: Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 1995;45:387-397
8. Prout GR Jr, Barton BA, Griffin PP, Friedell GH: Treated history of noninvasive grade 1 transitional cell carcinoma. J Urol 1992; 148:1413-1419.
9. Hudson MA, Herr HW: Carcinoma in situ of the bladder J Urol 1995;153:564-572.
10. Prout GR Jr, Griffin PP, Daly JJ: The outcome of conservative treatment of carcinoma in situ of the bladder. J Urol 1978;138:766-770.
11. Kaye KW, Lange PH Mode of presentation of invasive bladder cancer: reassessment of the problem. J Urol 1982;128:31-33.
12. Hopkins SC, Ford KS, Soloway MS: Invasive bladder cancer: support for screening. J Urol 1983;130:61-64.
13. Stockle M, Meyenburg W, Wellek S, et al: Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 1995;153:47-52.
14. Freiha F, Reese J, Torti FM: Randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996;155:495-500.
15. Skinner DG, Daniels JR, Russell CA, et al: The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991;145:459-464.
16. Loehrer PJ, Elson P, Dreicer R, et al: Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1994;12:483-488.
17. Williamson MP, Elder PA, Shaw ME, Devlin J, Knowles MA: p16(CDKN2) ts a major deletion tarsel at 9p21 in bladder cancer. Hum Mol Gen 1995;4:1569-1577.
18. Cairns P, Polascik TJ, Eby Y, et al: Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Gen 1995;11:210-212.
19. Sidransky D, Frost P, von Eschenbach A, et al: Clonal origin of bladder cancer. N Engl J Med 1992;326:737-740.
20. Nakopoulou L, Constantinides C, Papandropoulos J, et al: Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder carcinoma: comparison with DNA ploidy. Urology 1995;46:334-340.
21. Esrig D, Elmajian D, Groshen S, et al: Accumulation of nuclear p53 and tumor progression in bladder carcinoma. N Engl J Med 1994;331:1259-1264.
22. Benedict WF: Altered Rb expression is a prognostic clinical marker involved in human bladder tumorigenesis. [Review] J Cell Biochem (Suppl) 1992;161:69-71.
23. Cordon-Cardo L: Mutation of cell-cycle regulators - biological and clinical implications for human neoplasia. Am J Path 1995;147:545-560.
24. Harris AL, Hollstein M: Clinical implications of the p53 tumor suppressor gene. NEJM 1993;329:1318-1324.
25. Prout GR Jr, Koontz WW Jr, Coombs LJ, et al: Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J Urol 1983;130:677-680.
26. Cookson MS, Sarosdy MF: Management of stage T1 superficial bladder carcinoma with intravesical bacillus Calmette-Guérin therapy. [Review] J Urol 1992;148:797-801.
27. Lawrence WF, Messing EM, Bram LL. Cost-effectiveness of screening for bladder cancer using chemical reagent strips to detect microscopic hematuria. [Abstract] J Urol 1995;153 (Suppl):995A.
28. deVere White RW, Deitch AD: Evaluation of DNA flow cytometry as a screening test for bladder cancer. [Review] J Cell Biochem (Suppl) 1992;161:80-84.
29. Wheeless LL, Reeder JE, Han R, et al: Bladder irrigation specimens assayed by fluorescence in-situ hybridization to interphase nuclei. Cytometry 1994;17:319-326.
30. Golijanin D, Sherman Y, Shapiro A, Pode D: Detection of bladder tumors bv immunostaining of the Lewis X antigen in cells from voided urine. [Review] Urology 1995;46:173-177.
31. Bonner RB, Hemstreet III GP, Fradet Y, et al: Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells. Cancer 1993;72:2461-2469.
32. Grossman HB, Washington RW Jr, Carey TE, Lieben HB: Alterations in antigen expression in superficial bladder cancer. [Review] J Cell Biochem (Suppl) 1992;161:63-68.
33. Fradet Y, Tardif M, Bourget L, et al: Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Cancer Res 1990;50:432-437.
34. Messing EM: Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma Cancer Res 1990;50:2530-2537.
35. Mellon K, Wright C, Kelly P, et al: Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 1995;153:919-925.
36. Messing EM, Murphy-Brooks N: Recovery of epidermal growth factor in voided urine of patients with bladder cancer. Urology 1994;44:502-506.
37. Chodak GW, Haudenschild C, Gittes RF, Folkman J: Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder. Ann Surg 1980;192:762-771.
38. Nguyen M, Watanabe H, Hudson AE, et al: Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 1993;85:241-242.
39. Guirguis R, Schiffmann E, Liu B, et al: Detection of autocrine motility factor in urine as a marker of bladder cancer. J Natl Cancer Inst 1988;80:1203-1211.
40. Korman HJ, Peabody JO, Cerny JC, et al: Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder. J Urol 1996;155:347-349.
41. Hasui Y, Marutsuka K, Asada Y, Osada Y: Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer. Urology 1996;47:34-37.
42. D'Hallewin M, Baert L: Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J Urol 1996;155:475-476.
43. Soloway MS, Briggman JV, Carpinito GA, et al: Use of new tumor marker, urinary NMP22, in detection of occult or rapidly recurring transitional cell carcinoma of urinary tract following surgical treatment. J Urol 1996;156:363-367.
44. Brentnall TA: Microsatellite instability: Shifting concepts in tumorigenesis Am J Pathol 1995;147:561-563.
45. Mao L, Schoenberg MP, Scicchitano M, et al: Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996;271(5249):659-662.